Biomarkers of Traumatic Brain Injury

Dear Colleagues,

According to the definition of the BEST (Biomarkers, EndpointS, and other Tools) Resource (created by the FDA-NIH Biomarker Working Group), a biomarker could be a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or biological responses to an exposure or intervention, including therapeutic interventions. Biomarkers may include molecular, histologic, radiographic, or physiologic characteristics. Categories of biomarkers include: susceptibility/risk biomarker, diagnostic biomarker, monitoring biomarker, prognostic biomarker, predictive biomarker, response biomarker, safety biomarker.

With regard to the circulating protein biomarkers of traumatic brain injury (TBI), while some breakthroughs have recently been made in the field of diagnostic biomarkers (the implementation of the S100B protein to the Scandinavian guideline as a diagnostic tool for mild TBI and FDA clearance for the Banyan Brain Trauma Indicator Kit (GFAP + UCH-L1) for the diagnosis of mTBI in the USA) and recent studies have confirmed the prognostic power of the most commonly investigated biomarker molecules, there are still lots of uncertainties even regarding the exact diagnostic and/or prognostic capabilities of these few thus far relatively well-characterized/identified molecules.

From a broad perspective, there is still a clear unmet clinical need for efficient diagnostic, prognostic, monitoring, etc., biomarkers or biomarker combinations which could enhance the treatment as well as the long-term rehabilitation of TBI patients.

In light of this, our current Special Issue is open for the submission of any manuscripts which include clinical as well as experimental observations regarding biomarkers (primarily—but not restricted to—protein biomarkers) of traumatic brain injury.

Dr. Endre Czeiter
Dr. Krisztina Amrein
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• traumatic brain injury
• head injury
• biomarkers
• diagnostic
• prognostic
• experimental
• animal models
• clinical trials